A Phase 3 interventional study of QTI571 in Severe Pulmonary Arterial Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 3 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-18.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Pulmonary Arterial Hypertension by Novartis — 1 open to participants now, 1 under way, none of them phase 3. Pulmonary Arterial Hypertension · Novartis.
Among the 12 studies in Pulmonary Arterial Hypertension by Novartis, this one is the 10th largest by enrollment, is the only one that started in 2014, is one of 5 in phase 3, and was the 7th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →1 of the 12 studies in Pulmonary Arterial Hypertension by Novartis is open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 15 more countries
Ages 18–100 · Healthy volunteers
By country, each count listing its studies:
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 6
First in 2006; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 27 across the 12 interventional studies. Of the 11 that completed or were terminated, 11 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Pulmonary Arterial Hypertension by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To provide continued treatment to Pulmonary Arterial Hypertension (PAH) patients who are benefitting from treatment with QTI571.
This was a multi-center open label study to provide continued supply of QTI571 to patients in Japan who were treated in the extension study (A2301E1) and were judged by the investigator to benefit from continued QTI571 treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive QTI571 during 3 years.
Drug: QTI571
QTI571 200mg up to 400mg (depending on tolerability) taken orally, once a day.
Serious Adverse Events
All Serious Adverse Events were evaluated and reported for all participants receiving QTI571. 16 individual SAEs were observed in 5 subjects.
Time frame: Approximately 2.9 years
8 participants entered this study after completing the CQTI571A2301E1 study. All 8 participants discontinued study prematurely.
| Milestone | QTI571 |
|---|---|
| Started | 8 |
| Completed | 0 |
| Not completed | 8 |
| Withdrew: Adverse event | 1 |
| Withdrew: Physician decision | 7 |
All Serious Adverse Events were evaluated and reported for all participants receiving QTI571. 16 individual SAEs were observed in 5 subjects.
| participants | QTI571 |
|---|---|
| Cardiac disorders (5 events) | 5 |
| Infections and infestations (5 events) | 3 |
| Resp, thoracic,mediastinal & disorder (2 events) | 1 |
| Product issues (3 events) | 1 |
| Death (none) | 0 |
| Skin & subcutaneous tissue disorder(1 event) | 1 |
Collected over Adverse events were collected up to approximately 2.9 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| QTI571 | — | 5/8 (62.5%) | 0/8 (0%) |
| Event | QTI571 |
|---|---|
| Right ventricular failureCardiac disorders | 3/8 |
| Acute myocardial infarctionCardiac disorders | 1/8 |
| Supraventricular tachycardiaCardiac disorders | 1/8 |
| CellulitisInfections and infestations | 1/8 |
| GangreneInfections and infestations | 1/8 |
| Respiratory tract infectionInfections and infestations | 1/8 |
| Urinary tract infectionInfections and infestations | 1/8 |
| Device connection issueProduct Issues | 1/8 |
| Device occlusionProduct Issues | 1/8 |
| Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders | 1/8 |
| Age, Categorical(Participants) | QTI571 |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 7 |
| >=65 years | 1 |
| Sex: Female, Male(Participants) | QTI571 |
|---|---|
| Female | 8 |
| Male | 0 |
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Ran from Jan 2014 to primary completion in Oct 2016, 32 months.
Results were first posted in Jun 2019, 2 years 8 months after primary completion.
Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's 32 months is below that.
Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Imatinib
Pulmonary Arterial Hypertension →